Spots Global Cancer Trial Database for A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Official Title: A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Study ID: NCT00761696
Conditions
Interventions
Study Description
Brief Summary: The primary objectives of the study are: * To determine the safety and the maximum tolerated dose (MTD) of IPI-926 * To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) * To recommend a dose and schedule of IPI-926 for subsequent studies
Detailed Description: Study IPI-926-01 is a Phase 1, open-label, dose-escalation study in patients with advanced and/or metastatic solid tumor malignancies.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States
Stanford University, Redwood City, California, United States
University of Colorado Health Science Center, Aurora, Colorado, United States
Johns Hopkins Uninversity, Baltimore, Maryland, United States
McGill University Jewish General Hospital, Montreal, Quebec, Canada
Contact Details
Name: Robert Ross, MD
Affiliation: Infinity Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
